Nuclear Expression of KLF6 Tumor Suppressor Factor Is Highly Associated with Overexpression of ERBB2 Oncoprotein in Ductal Breast Carcinomas by Gehrau, Ricardo C. et al.
Nuclear Expression of KLF6 Tumor Suppressor Factor Is
Highly Associated with Overexpression of ERBB2
Oncoprotein in Ductal Breast Carcinomas
Ricardo C. Gehrau
1, Diego S. D’Astolfo
2, Catherine I. Dumur
3, Jose ´ L. Bocco
1*, Nicola ´s P. Koritschoner
1
1Centro de Investigaciones en Bioquı ´mica Clı ´nica e Inmunologı ´a (CIBICI-CONICET), Departamento de Bioquı ´mica Clı ´nica, Facultad de Ciencias Quı ´micas, Universidad
Nacional de Co ´rdoba, Co ´rdoba, Argentina, 2Centro de Investigaciones en Quı ´mica Biolo ´gica de Co ´rdoba (CIQUIBIC-CONICET), Facultad de Ciencias Quı ´micas, Universidad
Nacional de Co ´rdoba, Co ´rdoba, Argentina, 3Department of Pathology, Virginia Commonwealth University, Richmond, Virginia, United States of America
Abstract
Background: Kru ¨ppel-like factor 6 (KLF6) is an evolutionarily conserved and ubiquitously expressed protein that belongs to
the mammalian Sp1/KLF family of transcriptional regulators. Though KLF6 is a transcription factor and harbors a nuclear
localization signal it is not systematically located in the nucleus but it was detected in the cytoplasm of several tissues and
cell lines. Hence, it is still not fully settled whether the tumor suppressor function of KLF6 is directly associated with its ability
to regulate target genes.
Methodology/Principal Findings: In this study we analyzed KLF6 expression and sub-cellular distribution by
immunohistochemistry in several normal and tumor tissues in a microarray format representing fifteen human organs.
Results indicate that while both nuclear and cytoplasmic distribution of KLF6 is detected in normal breast tissues, breast
carcinomas express KLF6 mainly detected in the cytoplasm. Expression of KLF6 was further analyzed in breast cancer tissues
overexpressing ERBB2 oncoprotein, which is associated with poor disease prognosis and patient’s survival. The analysis of
48 ductal carcinomas revealed a significant population expressing KLF6 predominantly in the nuclear compartment (X
2
p=0.005; Fisher p=0.003). Moreover, this expression pattern correlates directly with early stage and small ductal breast
tumors and linked to metastatic events in lymph nodes.
Conclusions/Significance: Data are consistent with a preferential localization of KLF6 in the nuclear compartment of early
stage and small HER2-ERBB2 overexpressing ductal breast tumor cells, also presenting lymph node metastatic events. Thus,
KLF6 tumor suppressor could represent a new molecular marker candidate for tumor prognosis and/or a potential target for
therapy strategies.
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Introduction
Kru ¨ppel-like factor 6 (KLF6) belongs to a large family of
mammalian Sp1/KLF transcription factors that play critical
roles in regulating key cellular functions ranging from differen-
tiation to proliferation and apoptosis [1,2,3,4]. KLF6 is an
evolutionarily conserved and ubiquitously expressed protein that
was identified as an activator of pregnancy-specific genes [5,6,7].
Several independent reports proposed that KLF6 is a tumor
suppressor gene product due to downregulation of KLF6
expression or frequent somatic inactivating mutations were
found within the klf6 gene in prostate carcinoma, colorectal
tumors, glioblastoma, hepatocellular carcinoma and lung-
derived tumors [8,9,10,11,12,13,14,15]. Nevertheless, a number
of other studies established that genetic alterations of KLF6 were
infrequently observed in distinct types of human cancers or, in
addition the klf6 gene expression was enhanced in some tumors
[8,16,17,18,19,20,21].
More recently, it has been reported that target disruption of the
klf6 gene caused early embryonic lethality and severely impaired
embryonic stem cells proliferation [22]. In addition, p21
CIP1/WAF,
a transcriptional target gene for KLF6 in differentiated cells
[12,23], was not downregulated in klf6
2/2 embryos [22]. Most
importantly, in hepatoma cell lines the situation is particularly
interesting since KLF6 knockdown led to dephosphorylation of Rb
together with downregulation of Cyclin D1, which in turn strongly
impaired cell proliferation involving G1-S arrest [24]. Thus, the
phenotypes described in klf62/2 mice, stem cells and hepatoma
cell lines suggests that endogenous KLF6 is required for cell cycle
progression, thereby contrasting with its potential tumor-suppres-
sor activity. In agreement with these observations, knock down of
KLF6 expression mediated by siRNA lead to reduction in cell
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more susceptible to DNA-damage induced apoptosis [25].
On the other hand, it has been reported that KLF6 has the
ability to reduce cell proliferation rate through increased c-Jun
degradation by the proteasome dependent pathway upon tumor
promoter and proliferating cell signaling generated by phorbol 12-
myristate 13-acetate and ionomycin [26]. More recently, phorbol
12-myristate 13-acetate-induced growth arrest of non-small lung
cancer cells was mediated by induction of KLF6 expression
following PKC activation [27]. In addition, KLF6 mediates
inhibition of Cyclin D1/cdk4 activity, resulting in growth
inhibition [28]. Re-expression of wild type KLF6 into prostate
carcinoma PC-3 cells and non-small lung cancer cells, which
harbor loss-of-function mutations or downregulation of the
endogenous klf6 gene, respectively, enhanced growth suppression
and apoptosis [29,15].
Current available information clearly demonstrates the involve-
ment of KLF6 in the regulation of cell proliferation and apoptosis
which can influence tumor development. However, cell context
and/or biochemical signaling, interaction with specific transcrip-
tional partners and/or sub-cellular distribution of KLF6 could
manage the outcome of KLF6 function to different and opposite
tumor pathways. Thus, differential regulation of KLF6 under
specific cell environment provides a plausible explanation on the
divergent information published so far about the tumor suppressor
function of KLF6. In this regard, Guo and co-workers demon-
strated a decreased binding of KLF6 to its DNA binding sequence
on the Tissue Factor Pathway Inhibitor-2 (TFPI-2) gene due to
CpG hypermethylation in highly invasive breast cancer cell lines,
suggesting a tumor suppressor function of KLF6 [30]. However,
siRNA mediated knockdown of endogenous KLF6 in the MCF7
breast cancer-derived cell line lead to reduced cell proliferation
[25].
Breast cancer is the most common malignant, clinically
heterogeneous disease in women, and metastatic events occur-
rence at distant sites originated at the primary tumor is the main
cause of death. The characterization of the tumor aggressiveness of
patients with breast cancer reside in the study of both, clinical and
pathological parameters established by medical criteria such as
tumor size, axillaries lymph node status, histological grade and
angio-invasion. However, these clinical and pathological param-
eters seem to be not accurate enough for disease prognosis and
treatment follow-up. A large number of proteins have been
reported as potential molecular prognostic markers although few
of them such as uPA/PAI1, steroid-receptor expression and HER-
2/neu gene amplification and protein expression have been
established at clinical level (reviewed in [31,32,33,34,35,36]).
Within the Sp1/KLF family of transcription factors, only KLF4
and KLF5 have been further investigated in the context of breast
tumor environment. The transcript and protein levels of KLF4 are
increased during breast tumor progression and its nuclear
localization has been associated to an aggressive phenotype in
early stages of breast tumors [37,38]. In opposite, the transcript of
KLF5 is decreased in various breast cancer cell lines mainly as a
consequence of chromosomal deletion or degradation of the KLF5
protein by the proteasome dependent pathway [39,40,41].
However, high expression of KLF5 in breast cancer samples was
directly correlated with cell proliferation in vivo and with HER-2
expression level whereas patients had a shorter disease-free
survival and overall survival time than those with lower KLF5
expression [42].
As an essential step to gain knowledge about function of KLF6
in breast tumors, the expression pattern and sub-cellular
distribution of KLF6 protein was analyzed in samples of human
breast cancer along with the expression of ERBB2 as a tumor
aggressiveness marker. Interestingly, KLF6 was extensively
detected in the nucleus of HER-2/ERBB2-overexpressing breast
tumor cells whereas it was mainly cytoplasmic in the normal tissue
counterpart. Moreover, this KLF6 expression pattern tends to be
associated with small size and stage I ductal breast tumors, as well
as with axillary lymph node metastasis.
Results
Expression and Sub-Cellular Distribution of KLF6 in
Normal and Tumor Tissues
To determine the pattern of KLF6 protein and its sub-cellular
distribution in normal and tumor breast tissues by immunohisto-
chemistry, the specificity of the antibodies was controlled using
tissue sections of human term placenta, considering the high level
of KLF6 expression in this organ. The specificity of the anti-KLF6
monoclonal antibody (clone 2C11) was previously characterized
by immunoprecipitation and Western blot assays [26]. For
immunohistochemistry assays, the specificity of this antibody was
evaluated with respect to that of the commercial polyclonal Zf-9
anti-KLF6 antibody. Both antibodies developed similar staining
patterns in paraffin-embedded term placenta sections by immu-
nohistochemistry assays, showing nuclear and cytoplasmic local-
ization of KLF6 in peripheral chorionic villous cells, and in inner
cells of placenta (Fig. 1A). This result indicates that the specificity
of the monoclonal antibody (clone 2C11) is suitable for detection
of KLF6 in tissue sections by immunohistochemistry, given similar
results than the commercial anti Zf9 polyclonal antibody. Even
similar antibodies staining patterns were found in a breast
carcinoma tissue section (Fig. S1).
Next, the pattern of KLF6 protein was analyzed by
immunohistochemistry assays in several normal and tumor tissue
sections derived from paraffin-embedded samples spotted in an
array. Results clearly showed a specific and significant staining
for KLF6 in both normal and tumor tissues with varied intensity.
Also the sub-cellular distribution of KLF6 was confined to the
cytoplasm compartment in tumor tissues in contrast with a
uniform nuclear and cytoplasmic distribution for each histological
normal counterpart (Fig. S2 and Table S1). These results are in
good agreement with previous studies showing a ubiquitous
expression of KLF6 at the mRNA level [6,7], and in this work it
is shown that substantial amount of KLF6 protein is mainly
accumulated in the cytoplasmic compartment of cancer samples.
Interestingly, this expression and sub-cellular distribution pattern
was not observed in breast cancer tissue sections. In contrast to
other type of tumor tissues, KLF6 expression was confined in a
large extent and almost exclusively in the nuclear compartment in
a high percentage of these breast tumors tissues (Fig. 2, left panel,
L1). Similar KLF6 distribution was detected in a different lot of
tumor tissue microarrays (Fig. 2, left panel, L2a–c). These results
suggest a specific regulation of KLF6 polypeptide in the context
of breast tumor, leading to a preferential localization within the
nucleus.
ERBB2 expression constitutes a well known marker of breast
tumors aggressiveness and its overexpression is associated with a
worse prognostic and reduced survival [31]. To assess the
relationship of KLF6 protein expression with the malignancy
degree of each breast tumor analyzed in this study, the ERBB2
expression level was determined in both lots of tumor tissues
microarrays. Interestingly, though ERBB2 expression level varied
in different breast tumor samples, tissues having a nuclear
localization of KLF6 show higher expression of ERBB2, as
observed in both tissues lots (Fig. 2, right panel). It is important to
KLF6 in Ductal Breast Tumors
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tissue area where KLF6 was detected.
Sub-Cellular Localization of KLF6 in Breast Cancer Tissues
As shown previously, nuclear localization of KLF6 observed in
cells of breast tumor tissue sections is in line with high expression
levels of ERBB2. These results prompted us to extend the analysis
Figure 1. Immunohistochemical assay for KLF6 in placenta
tissue section. Immunohistochemistry assays were performed as
described in Material and Methods. The specific stain is shown as a
brown precipitate and nuclei were blue counterstained with hematox-
ylin. Magnification is 6006. A. Stain pattern obtained for the
commercial anti-KLF6 polyclonal antibody (Zf9, top) and for in house
produced anti-KLF6 monoclonal antibody (clone 2C11, bottom) in term
placenta tissue sections. B. Background control of the secondary
detection complex EnVisionH System Peroxidase Labeled Polymer
(Dako, Carpinteira, USA). The placenta tissue section was incubated
only with primary antibody dilution buffer, and the secondary detection
complex mentioned above.
doi:10.1371/journal.pone.0008929.g001
Figure 2. KLF6 and ERBB2 expression in breast cancer tissues.
Immunohistochemistry assays in two lots of Tumor tissues Microarray
from DAKO (CheckBoard Tissue Tumor human Tissues, T1064, Dako,
USA). Tissues were incubated with anti-KLF6 (clone 2C11, left panel)o r
anti-ERBB2 (right panel) antibodies. Lot 1 (#00071) is represented in the
panel L1, and Lot 2 (#00111) in panels L2a, L2b and L2c. The KLF6 and
ERBB2 stains were photographed in the equivalent area of the tissue
section at 4006of magnification.
doi:10.1371/journal.pone.0008929.g002
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population. Thus, an independent tissue microarray was analyzed,
which contains tissues sections from 60 clinical cases comprising
an assortment of human breast tumor types (LandMark
TM).
Patient’s clinical data, including tumor size, histological grade and
stage, and lymph nodes analysis for each case are summarized in
Table 1 and detailed by clinical case in Table S2.
Immunohistochemical assays revealed that epithelial cells of the
whole breast tumor tissues population developed a specific staining
for KLF6 (Fig. 3 left panel, Table 2 and Table S3). Interestingly,
the stain intensity was consistently higher than of a fibroadenoma
tissue sample, which expressed low levels of KLF6 that was
detected systematically in the cytoplasmic compartment. It is
important to remark that no nuclear KLF6 staining was detected
in the fibroadenoma breast tissue (Fig. 3 row i, left panel; Table
S3). This tissue sample was used as control tissue because the
architecture and cellular phenotype of a non-pathologic mammary
gland tissue are relatively conserved as in normal tissue. Following,
the KLF6 immunostaining was also positive in the cytoplasmic
compartment of the complete breast tumor tissues population.
More importantly, 57.6% (34/59) of the analyzed breast tumors
tissues whole population exhibited positive nuclear immunostain
for KLF6 (Table 2A). This result is in accordance with the
previous observations detailed above.
HER2-ERBB2 Expression in the Whole Breast Tumor
Tissue Population
Apart of the KLF6 expression analysis, immunohistochemical
assays were performed to determine the HER2-ERBB2 aggres-
siveness marker status in the studied breast tumor population. The
positive HER2-ERBB2 cut-off criterion is indicated in Material
and Methods. Results indicated that 54.2% (32/59) of the breast
tumor population overexpressed HER2-ERBB2 (Table 2A). It is
important to mention that abnormal high levels of HER2-ERBB2
are present in approximately 18–20% of breast cancers ([43] and
references therein). Nevertheless, many researchers agree that it is
amplified and overexpressed in 32% to 55% of DCIS lesions
[33,34,36]. In this sense, the percentage of HER-ERBB2
overexpressing breast tumor tissues obtained in the present work
is in line with the prevalence already reported considering in
addition that the tumors population is composed by an assortment
of invasive and non-invasive tumor types.
Significant Correlation of Nuclear KLF6 and HER2-ERBB2
Overexpression
Next, to evaluate the significance between the nuclear KLF6 and
HER2-ERBB2 overexpression, immunostain intensities of both
proteins were estimated for eachbreast tumor tissue. Interestingly, a
significant subpopulation (chi-square p=0.001, Pearson p,0.001)
of twenty-five breast tumor tissues overexpressing HER2-ERBB2
were positive for nuclear KLF6 (Table 2B). For the remaining
tumor tissues, only sixteen breast tumor tissues were single positive
(ninefornuclearKLF6,andsevenforHER2-ERBB2),and eighteen
were negative for both immunostains (Table 2B).
This analysis clearly suggests that KLF6 may be nuclear
localized in aggressive breast tumor tissues determined by the
HER2-ERBB2 overexpression status.
KLF6 Nuclear Localization and ERBB2 Overexpression in
Ductal Breast Tumor Tissues
The tumor tissues microarray included forty-eight ductal breast
tumors tissue sections, which represents the major population.
Hence, to better define the KLF6 protein sub-cellular localization
significance, the analysis was focused on this tissue sub-population.
As described in the results section above, the sub-cellular
distribution of KLF6 showed a pattern of variable intensity
immunostain at the nuclear and cytoplasmic regions, which was
referred as immunoscores values (Table S3). A scatter-plot analysis
revealed that fifty-eight percent (28/48) of breast ductal tumor
tissues express KLF6 both in the nucleus and cytoplasm (Fig. 4A);
additionally, ductal breast tumor tissues expressing and non-
expressing nuclear KLF6 revealed a significant increase
(p=0.005; student t test) of the cytoplasmic stain (score mean 2.56
versus 1.99, respectively; see Fig. 4A and Table S3). Regarding
HER2-ERBB2 expression, results of immunohistochemical assays
showed that fifty-five percent (28/48) of these samples overex-
pressed ERBB2 protein, giving different stain intensity levels (Fig. 3,
right panel, and see Table S3). Within ductal breast tumors, the
percentage of ERBB2 overexpressing tissues was almost maintained
to those determined for the whole breast tumors population.
Following, the KLF6 nuclear localization was related to the
HER2-ERBB2 overexpression in ductal breast tumor tissues. A
significant subpopulation of the ductal breast tumor collection
[44% (21/48)] showed positive immunostain for nuclear KLF6
and ERBB2 overexpression (Chi-square and Fisher exact tests p
values equal to 0.005 and 0.003, respectively; Fig. 4B); analysis of
the tumor population overexpressing only ERBB2 revealed that
the seventy-eight percent (21/27) of ductal breast tumor tissues
expressed nuclear KLF6 (Table 3). Moreover, within the tumor
population expressing nuclear KLF6, it was found that seventy-five
percent (21/28) of the cases overexpressed ERBB2 (Table 3). In
contrast, ERBB2-negative ductal carcinomas showed a significant
lower KLF6 stain scores (p=0.007; student t test) and absence of
Table 1. Characteristic of the studied breast carcinomas
population.
Parameter Subcategory Value
No. of patients 60
Median age, years (range) 65 (31–92)
Tumor stage, n (%) I 17 (28.3)
II 36 (60.0)
III 6 (10.0)
IV 1 (1.7)
Histological grade, n (%) 1 14 (23.3)
2 34 (56.7)
3 12 (20.0)
Histopathologic type, n (%) Ductal 48 (80.0)
Lobular
(1) 6 (10.0)
Cribiform 2 (3.2)
Metaplastic 2 (3.2)
Mucinous 1 (1.7)
Tubular 1 (1.7)
Medullary 1 (1.7)
Median tumor size, cm (range) 2.7 (0.7–8.5)
Lymph nodes, n (%) Negative 11 (18.3)
Positive 15 (25.0)
No determined 34 (56.7)
(1)One lobular breast carcinoma tissue was destroyed, and thus not included
into the analysis.
doi:10.1371/journal.pone.0008929.t001
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carcinomas (score mean 1.9 versus 2.5, respectively; Table S3).
In agreement with this observation, a similar direct correlation
between the KLF6 and ERBB2 expression was found at the RNA
level of the klf6 and HER2/neu –encoding genes in an independent
study of breast tumors population, as determined by RNA
microarray hybridization (Fig. S3).
Overall these observations clearly suggest that the nuclear
expression of KLF6 frequently occurs in ERBB2-overexpressing
ductal breast tumor cases, which is in line with tumor
aggressiveness. In addition, regardless its sub-cellular distribution,
the global klf6 gene expression seems to be augmented in
accordance with the HER2/neu gene expression level in this type
of ERBB2-overexpressing ductal breast tumors.
Estrogen Receptor Alpha Status
To validate our previous results regarding the nuclear
distribution of KLF6 in ERBB2-overexpressing breast tumors
Figure 3. KLF6 and ERBB2 expression in ductal breast cancer tissues. Immunohistochemistry assays in LandMark LD Breast TMA tissue
microarray (Ambion, Austin, TX, USA). Tissues were incubated with the anti-KLF6 and anti-ERBB2 antibodies. The left panel of the KLF6 and ERBB2
column pictures has 4006magnification. The square into each 4006picture indicates the area photographed at 10006and showed in the right
panel of each column. Photomicrographs of the immunostain for KLF6 and ERBB2 were taken from equivalent tissue areas. The horizontal panels
represents the KLF6 and ERBB2 expression in a fibroadenoma tissue (i) and four representative cases for both positive nuclear KLF6 and ERBB2 (ii),
negative nuclear KLF6 and positive ERBB2 (iii), positive nuclear KLF6 and negative ERBB2 (iv), and both negative nuclear KLF6 and ERBB2 (v). Tissues in
ii–v correspond to the cases 40, 18, 45, and 6, respectively, described in Tables S2 and S3.
doi:10.1371/journal.pone.0008929.g003
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additional established risk factor for breast cancer. It is well known
that Estrogen Receptor alpha are expressed in up to 70% of all
breast cancers [31].
Consistently with this, thirty-eight (63.3%) tissues of the total
breast tumor population were positive for Estrogen Receptor
alpha. Similar results were observed in the ductal breast tumor
subpopulation, where thirty tissues (62.5%) were positive for
Estrogen Receptor alpha (Table 3A).
Following we examined the Estrogen Receptor alpha-a status
depending on nuclear KLF6 distribution and ERBB2-overexpres-
sion in ductal breast tumor tissues. In this regard, seventy-one
percent (20/28) of nuclear KLF6 positive tissues were also positive
for Estrogen Receptor alpha; in comparison, sixty-four percent of
ERBB2-overexpressing tissues also expressed Estrogen Receptor
alpha. More importantly, seventy-one percent (15/21) of the
ductal breast tumor tissues sub-population with both nuclear
KLF6 distribution and ERBB2-overexpression also were positive
for Estrogen Receptor alpha (Table 3B). This finding is of great
importance because this result indicates high correlation of the
nuclear expression of KLF6 in ductal breast tumor tissues with
other established risk factor, and also together with ERBB2.
Clinico-Pathological Parameters
To determine the relationship of nuclear KLF6 distribution in
ductal carcinomas, the clinico-pathological parameters were
analyzed in those tumor tissues overexpressing ERBB2. TNM
staging system criteria respect to the size and tumor stage, and
analysis of axillaries lymph nodes was used for evaluation of
clinical provided data [44]. The ERBB2 overexpressing ductal
breast carcinomas were analyzed with respect to size, tumor stage
and histological grade, presence or absence of axillary lymph node
metastasis, and nuclear KLF6 immunostain.
As described in Table 4, the ductal breast tumor population is
mainly contained in small and medium tumors sizes [(23/27, 85%)
with ,2.0 cm and 2.1–5.0 cm, respectively], and stage I and II
tumors (24/27, 89%). KLF6 is preferentially expressed in 91%
(10/11) of small ERBB2 overexpressing ductal breast tumors,
while the expression percentage is homogeneous in the remaining
tumor size subpopulation. Similar results were obtained with
respect to tumor stages and histological grades. In this regard, 86%
(6/7) of stage I-ERBB2 overexpressing ductal breast tumors have
positive nuclear stain for KLF6. A similar pattern was observed for
stage II-ERBB2 overexpressing tumors though in a lower
proportion (76%; 13/17).
Histological grades of tumors were also analyzed. ERBB2
overexpressing ductal breast tumors did not revealed a preferential
relationship of histological grades and nuclear KLF6 expression.
In this sense, nuclear distribution of KLF6 was observed in 100%
(7/7) in ERBB2 overexpressing ductal breast tumors with
histological grade 1. Nevertheless, similar results were found for
tumors with histological grades 2 and 3 (60%, 9/15; 100%, 5/5,
respectively; Table 4). Due to the relative low number of tumor
cases, only for histological grade was possible to establish a
significant correlation by chi square statistical analysis, and non
significant statistical results were obtained respect to the size and
stages of the breast tumor cases (see Table 4). Similar statistical
results were obtained by analyzing axillary lymph nodes
metastasis.
Fifty-two percent (14/27) of patients included in the study
population overexpressing ERBB2 were analyzed for metastatic
lymph nodes (Table 4). Interestingly, the greater percentage of
metastatic (positive) lymph nodes occurred in patients with ERBB2
overexpressing ductal breast tumors showing in addition positive
nuclear stain for KLF6 (88%, 7/8), and represent the major
subpopulation of cases with analyzed axillary lymph nodes.
Negative lymph nodes were equally distributed between positive
or negative KLF6 nuclear stained, ERBB2 overexpressing tumors
(Table 4).
It is important to mention that the low number of analyzed
ductal breast tumor cases is not enough for statistical analysis.
Nevertheless, the obtained results suggest that a high percentage of
ERBB2-overexpressing ductal carcinomas may express KLF6 at
the nuclear compartment during early stages of development. In
addition, patients harboring ductal breast carcinomas correspond-
ing to the analyzed population seem to be prone to develop
metastasis, in order to the prevalent percentage of positive lymph
nodes in patients affected by this tumor type.
Discussion
Expression and sub-cellular distribution of KLF6 was deter-
mined in normal and tumor tissues by using tissue microarrays and
immunohistochemistry with two specific antibodies. In accordance
with previous reports, we found a ubiquitous expression of KLF6
Table 2. Analysis of KLF6 and HER2-ERBB2 proteins in breast tumor tissues.
A. Immunohistochemical analysis for nuclear KLF6 and HER2-ERBB2 in the total breast tumor tissues population
Protein Status Number of tissues (%)
HER2/ERBB2 Not overexpressed 27 (45.8)
Overexpressed 32 (54.2)
Nuclear KLF6 Positive 34 (57.6)
Negative 25 (42.4)
B. Correlative analysis of nuclear KLF6 expression and HER2-ERBB2 overexpression
Nuclear KLF6 HER2/ERBB2 Number of Tissues (%) Chi-square p Value
Positive Overexpressed 25 (42.4) 0.001
Positive Not overexpressed 9 (15.3)
Negative Overexpressed 7 (11.8)
Negative Not overexpressed 18 (30.5)
doi:10.1371/journal.pone.0008929.t002
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sub-cellular distribution is mainly nuclear in normal tissues in
contrast with an entirely cytoplasmic expression in the tumor
counterpart (Fig. S2 and Table S1). This expression pattern
completely matches with the role as tumor suppressor described
for KLF6 since mutations of klf6 gene were associated to different
human neoplasms [9,10,11,12,13,14,15,45]. For instance, it is
possible to hypothesize that absence of a nuclear expression of
KLF6 prevents the regulation of specific target genes involved in
negative control of cell growth.
Despite of the expression pattern tendency described above, the
KLF6 expression was found markedly changed in a significant
percentage of breast tumor tissues, where it was mostly detected in
the nucleus of ERBB2-overexpressing carcinoma cells (Fig. 2).
Breast cancer represents a heterogeneous disease in oncology and
the ERBB2 status has become a routine prognostic and predictive
factor in standard measurements in the management of patients
together with Estrogen Receptor alpha, which are expressed in up
to 70% of all breast cancers [31,32]. HER-2/neu oncogene encodes
a member of the epidermal growth factor receptor (EGFR) family
of tyrosine kinases and is located on chromosome 17q21.
Abnormal high levels of ERBB2 are present in approximately
18–20% of breast cancers and gene amplification is the
predominant mechanism leading to ERBB2 overexpression which
in turn enhance cell proliferation ([43] and references therein).
KLF6 expression and sub-cellular distribution was further
analyzed in breast cancer samples, mainly focused on ductal
breast tumor tissue cases. Concerning to the ERBB2 status, many
researchers agree that it is amplified and overexpressed in 32% to
55% of DCIS lesions. Moreover, HER-2/neu gene amplification
and overexpression in ductal tumors is more common in higher
grade rather than in lower grade lesions, and also has been
associated with aneuploidy and higher proliferative indexes
[33,34,36]. In focus on the ERBB2-positive ductal breast tumor
population, the results presented in this work demonstrated that
there is a significant percentage of tissues that express nuclear
KLF6 (Fig. 3 and Table 2). Interestingly, this expression pattern
was also found highly correlated with a positive stain for Estrogen
Receptor that represents other established risk factor, and thus
further validates our results (Table 3B). An independent analysis
performed by RNA microarrays hybridization of samples obtained
from a distinct breast tumor group indicated a direct correlation
between the expression level of klf6 and HER-2/neu genes (Fig. S3).
In addition, KLF6 knockdown in MCF7 breast cancer cells leads
to a cell cycle arrest affecting the G1-S transition (Table S4). Thus,
despite of the limited knowledge about the KLF6 role in breast
cancer, our results strongly indicate that KLF6 is expressed in
breast tumor tissues, even at higher levels than a control breast
tissue (Fig. 3, Table 2, and Table S3). Nuclear localization of
KLF6 together with an ERBB2-overexpression suggests that
KLF6 function is associated with the malignant phenotype, grow
and development of this type of breast tumor.
Though KLF6 is a transcription factor having a conserved
nuclear localization signal and the analysis of its primary amino
acid sequence predicts a nuclear localization of this protein, KLF6
is frequently detected in the cytoplasm of several tissues and cell
lines as in HEK and Cos-7 cells (Slavin et al., 2004). However,
KLF6 is mainly located in the nucleus in other cell line like A 549
derived from lung carcinoma (V. Andreoli and J.L. Bocco,
unpublished). Similar results showing nuclear and/or cytoplasmic
distribution was observed for endogenous KLF6 in normal and
tumor tissues by immunohistochemistry ([46]; this work). Follow-
ing these results, it is interesting to hypothesize that some
endogenous or external signals, still not known, could regulate
KLF6 distribution in specific cells and in some ones, like in ductal
breast cancer cells; these signals could be constitutively activated.
In this sense, cell stimulation mediated by phorbol esters alone or
in combination with ionomycin, led GFP-tagged KLF6 through
the nuclear compartment [26]. Additionally, endogenous KLF6
translocated to the nucleus upon activation of hepatic stellate cells
and denudation of endothelial HUVEC cells [47,48]. Thus, the
dynamics of nuclear localization of KLF6 seems to be finely tuned
in normal cells; alterations of this regulatory mechanism in the
context of ductal breast cancer cells might promote constitutive
Figure 4. Association between nuclear KLF6 expression and
ERBB2-overexpression in ductal breast tumor tissues. The
immunohistochemical staining intensity for KLF6 (nuclear and cyto-
plasmic) and c-erbB2 (cytoplasmic membrane) is represented as scores
used a 0.0–4.0 scale estimated over a characteristic cell cluster of each
tissue. The scores estimation was obtained as described [50,51] (see
Material and Methods). A score of 1.0 represent less than 10% of
positive labeled cells and was set as the cutoff value. A. Scatter plot
analysis of nuclear KLF6 versus cytoplasmic KLF6. The oval includes
positive tissue for both staining patterns. B. Scatter plot analysis of
nuclear KLF6 versus ERBB2 immunostains. Filled lines settled at 0.0 and
1.0 score indicate cutoff values and partite four populations determined
by the KLF6 and ERBB2 staining. The percentage of each population is
represented into a gray circle. Especially for the double-negative
population (minus 1.0 and 0.0 scores) a point could represent two or
more cases.
doi:10.1371/journal.pone.0008929.g004
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with a malignant phenotype, as shown here.
Alternatively, the half life of cytoplasmic KLF6 protein could be
shorter due to a mechanism still to be revealed. However,
independently of which mechanism takes place, it was recently
shown that reduction or absence of KLF6 abrogates the negative
control of breast cancer cell proliferation triggered by Estrogen
Receptor alpha through the signaling pathway mediated by c-Src
and Akt activation [49]. Thus, in addition to its nuclear localization
and its function as a transcription factor, cytoplasmic KLF6 is able
to interact with c-Src protein and thereby interferes with Estrogen
Receptor alpha-mediated cell growth of breast cancer cells [49].
Table 3. Analysis of the nuclear KLF6 expression along with the Estrogen receptor alpha status and HER2-ERBB2 overexpression in
breast tumor tissues.
A. Immunohistochemical analysis for Estrogen Receptors alpha status
Breast tumors population Estrogen Receptor Status Number of tissues (%)
Total Positive 38 (63.3)
Negative 21 (35.0)
ND 1 (1.7)
Ductal Positive 30 (62.5)
Negative 17 (35.4)
ND 1 (2.1)
ND: None determined
B. Nuclear KLF6 expression and ERBB2 overexpression versus Estrogen Receptors alpha status in ductal breast tumor tissues
Nuclear KLF6/ERBB2 Total Number of tissues Estrogen Receptor Number of Tissues (%)
Positive/Overexpressed 21 Positive 15 (71.4)
Negative 6 (28.6)
Positive/Not overexpressed* 7* Positive 5 (71.4)
Negative 1 (14.3)
Negative/Overexpressed 6 Positive 3 (50.0)
Negative 3 (50.0)
Negative/Not overexpressed 14 Positive 7 (50.0)
Negative 7 (50.0)
(*)One tissue was not assessed for Estrogen Receptor alpha status due to it was destroyed.
doi:10.1371/journal.pone.0008929.t003
Table 4. Clinicopathological parameters of ERBB2-overexpressing ductal breast tumors and nuclear KLF6.
Parameter Subcategory Positive KLF6 (%) Negative KLF6 (%) Number of Cases Chi-square p value
Size ,2.0 cm 10 (91) 1 (9) 11 0.385
2.1–5.0 cm 8 (67) 4 (33) 12
.5.1 cm 1 (50) 1 (50) 2
ND 2 (100) 0 (0.0) 2
Stage I 6 (86) 1 (14) 7 0.694
II 13 (76) 4 (24) 17
III 1 (50) 1 (50) 2
IV 1 (100) 0 (0.0) 1
Histological grade 1 7 (100) 0 (0.0) 7 0.046
2 9 (60) 6 (40) 15
3 5 (100) 0 (0.0) 5
Lymph nodes Positive 7 (60) 1 (40) 0.177
Negative 3 (50) 3 (50)
ND 11 (75) 2 (25)
Total tissues 21 (78) 6 (22) 27
ND: No determined.
doi:10.1371/journal.pone.0008929.t004
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accessibility to specific gene promoters in the context of the
chromatin structure of these particular cells. The knowledge of the
complete set of target genes regulated by KLF6 in ductal breast
cancer is a huge task to be undertaken to gain further insights
about KLF6 in this pathology.
There is a continual drive to identify markers that will aid in
predicting prognosis and response to therapy of breast carcinomas.
They are also fundamental for categorizing patients into different
prognostic groups, when combined with information regarding
tumor size, grade, lymph-vascular invasion and nodal stage
(reviewed in [31,32,33,34,36]). To further understand the impact
of nuclear expression of KLF6 in ERBB2-overexpressing ductal
breast tumors we compare this stain pattern respect to clinico-
pathological parameter such as tumor stage, histological grade and
size, and lymph node involvement. Given its histological
characteristics, DCIS breast tumors have no metastatic potential,
but from 1% to 2% of patients with a diagnosis of pure ductal
breast tumor subsequently develop metastases either because of
occult invasion or because of the progression of unsuspected
residual disease to invasive breast cancer [36]. In this sense,
ERBB2 detection is associated with high-grade tumors, lymph
node involvement, a higher rate of disease recurrence and
mortality, and thus a poor prognosis [31]. Although we have
analyzed a small number of cases, in this report we further suggest
that KLF6 is nuclear expressed in a significant percentage of
ERBB2-overexpressing ductal breast tumors, and this nuclear
stain pattern may be related to the malignancy and aggressiveness
together with ERBB2-overexpression in early stage and small
ductal breast tumors because of the presence of metastatic event in
lymph nodes of patient harboring this tumor type.
Although is still early to fully understand the KLF6 function in
tumorigenesis, results of this work suggest that the tumor
suppressor function described for KLF6 could be recruited and/
or subverted in the context of breast cancer environment,
contributing to tumor development.
This report represents the first step of an effort to elucidate the
KLF6 function within the breast carcinoma environment, essential
to understand the contribution of KLF6 for breast cancer
pathogenesis and also as a new molecular marker candidate for
prognosis and therapy.
Materials and Methods
Tissue Procurement
Checkerboard Multi-Tumor and Multi-Normal Tissue micro-
Array containing paraffin-embedded normal or tumor tissues
samples of multiple human organs and placenta were purchased
from Dako, Carpinteria (CA, USA). The KLF6 expression in
breast tumors tissues was determined in LandMark LD Breast
TMA tissue array, which contain tissue sample from 60 breast
cancer cases (Ambion, Austin, TX, USA). General information of
patient and tumor features as age, sex, axillaries lymph nodes
status, tumor type, stage, and size are summarized in the Table 1
and Table S2.
Immunohistochemistry Assay
The tissue micro-Arrays were deparaffinized by treating twice
with xylene for 5 min and hydrated with serial aqueous-increased
ethanol solutions. Heat-induced epitope retrieval of deparaffinized
tissues was performed by using Target Retrieval Solution (Dako,
CA, USA) at a temperature range of 95–99uC for 20 min and
following blocked with 10% inactivated Fetal Calf Serum in PBS
for 30 min at room temperature. Endogenous peroxidase tissue
activity was blocked with Peroxidase Blocking Reagent (Dako, CA,
USA) for 5 min at room temperature. Blocked tissues were
incubated overnight at 4uC in a humidified chamber with a
suitable dilution of primary antibody in Antibody Diluent with
Background Reducing Component Solution (Dako, CA, USA).
Non-attached primary antibody was removed by washing three
times with PBS avoiding tissue drying. The immunodetection was
performed by incubating the tissues with Envision System
Peroxidase Labeled Polymer (Dako, CA, USA) for 30 min at
room temperature. Diaminobenzidine (DAB; Dako, CA, USA)
was used for chromogenic reaction and Mayer’s hematoxylin
(Lillie’s Modification; Dako, CA, USA) for nuclear counterstain.
Antibodies
Immunohistochemistry assays were performed with an anti-
KLF6 mouse monoclonal antibody (clone 2C11, 1:150) whose
specificity was previously determined [26], or using the commer-
cial anti-KLF6 polyclonal antibody (anti-Zf9; R-173, 1:50; Santa
Cruz Biotech., USA). Term placenta tissue sections (Dako,
Carpinteira, CA, USA), where endogenous KLF6 is highly
expressed, were used to control the specificity of anti-KLF6
antibodies and Envision System Peroxidase Labeled Polymer
(Dako, Carpinteira, CA, USA, Fig. 1A and 1B, respectively). A
breast tumor tissue section (Dako, Carpinteira, CA, USA) was also
used for checking antibodies staining patterns (Fig. S1). The
expression of ERBB2 was determined with a rabbit polyclonal
antibody anti-human c-erbB2 oncoprotein (1:200; A0485, Dako
Carpinteira, USA), widely used for immunohistochemistry tests in
patients [31].
Estrogen Receptor Alpha
The Estrogen Receptor alpha status of breast tissue samples was
determined at a private clinical diagnosis institute by immunohis-
tochemical staining using the automated system Dako Autostainer
Universal Staining. Epitope retrieval was induced by microwave
heating using 0.01 M citrate retrieval solution (pH 6.0).
Immunohistochemistry assays for Estrogen Receptor alpha
detection were performed with an anti-Estrogen Receptor alpha
mouse monoclonal antibody (clone ER 6F11, NCL-L-ER-6F11,
1:100, Novocastra, UK). The immunodetection was performed by
incubating the tissues with Dako LSAB+ System-HRP (Dako, CA,
USA). Estrogen Receptor alpha expression was considered positive
when at least 10% of the tumor cells showed uniform nuclear
staining (reviewed in [31]).
Immunoscoring
The immunohistochemical stain intensity of individual cells was
scored on a scale of 0 to 4, representing no staining (0) to highest
staining intensity (4), from a representative cell cluster of each
tissue. To calculate immunoscores, the proportion of cells
(percentage) at each immunostain intensity was multiplied by the
corresponding intensity value and these products were added to
obtain an immunostain score ranging from 0 to 4 as previously
described [50,51]. For KLF6, the immunostain intensity was
evaluated in both nucleus and cytoplasm cell compartment. HER-
2/ERBB2 overexpression was considered positive when the 30%
(staining score higher than 1.0) of the tumor cells showed uniform
intense membranous staining according to the recommendations
of The American Society of Clinical Oncology/College of
American Pathologists (ASCO/CAP) published in January 2007
[52]. The immunostaining intensity was blindly and independently
defined by two individual investigators. Discordances were
reconciled with a new stain intensity definition and the obtained
scores were averaged.
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Association between nuclear KLF6 localization and HER-2/
ERBB2 as one of the most effective breast tumor aggressiveness
marker as well as patients’ characteristics and histological
parameters within the tissue population was assessed using
contingency tables analysis (Chi-square X
2 test) including Yate’s
continuous correction, and validated with Fisher’s exact test.
Differences within immunostain intensity scores among nuclear or
cytoplasmic mark for KLF6 and cytoplasmic membrane for
ERBB2 were evaluated by using student t test. Significant
differences were considered as P,0.05 (two-tails).
Supporting Information
Figure S1 Experimental control of immunohistochemitry assays
in a breast tumor tissue. Control experiment of the stain pattern
obtained without primary antibody for background control (non-
antibody, left), with the polyclonal (anti-Zf9) or with the
monoclonal (clone 2C11) anti-KLF6 antibodies (middle and right
panels respectively; see also legend to Fig. 1). The blue stain is due
to hematoxylin as a nuclei counterstain. Upper panel shows
pictures taken at 2006magnification. The square into each 2006
picture indicates the photographed area at 10006that are shown
at the lower panel, as indicated. Photomicrographs of the
immunostain for KLF6 were taken from equivalent tissue areas.
Found at: doi:10.1371/journal.pone.0008929.s001 (4.80 MB TIF)
Figure S2 KLF6 immunostain in normal tissue and its
homologous tumoral-derived specie. Immunohistochemical assays
for KLF6 using Multi-Tumor and Multi-Normal Tissue micro-
Array (TMA) incubated with clone 2C11 monoclonal antibody as
described in legend to Fig. 1. The represented organ is mentioned
on the top for normal (upper panel) and tumor (lower panel) status.
Magnification: 10006. Specific stain is shown in brown and nuclei
in blue, counterstained with hematoxylin.
Found at: doi:10.1371/journal.pone.0008929.s002 (4.49 MB TIF)
Figure S3 klf6 and HER2/neu genes expression in breast tumor
tissues. The expression of both klf6 and HER-2/neu genes were
analyzed from existing microarray data for 21 human breast
cancer tissue samples corresponding to HER2/neu non-amplified
tumors. The expression of each gene is represented as arbitrary
units (AU). A. Two groups were defined with differential
expression levels. The two groups were discriminated by a cut-
off value represented by an ERBB2 expression level of 800 AU. An
oval enclose each group name as Group 1 (upper oval) and Group
2 (lower oval). B. Group 1: breast cancer tissues with ERBB2 levels
above 800 AU (Pearson’s R: 0.713). C. Group 2 with ERBB2
levels below 800 AU (Pearson’s R: 0.706).
Found at: doi:10.1371/journal.pone.0008929.s003 (0.15 MB TIF)
Table S1 KLF6 expression and sub-cellular distribution in
normal and tumor tissues. Stain intensity as null (2) to strong
(++++) NA: no available tissue.
Found at: doi:10.1371/journal.pone.0008929.s004 (0.04 MB
DOC)
Table S2 Individual patients’ clinical characteristics and immu-
nohistochemical analysis for KLF6 and ERBB2. Tumor size is
represented in centimeters (cm). Patient’s age represented in years.
pT: staging designation representing size and infiltration of the
tumor. pN: lymph node involvement (0: no involvement/1 lymph
nodes involved). pN=X: none analyzed lymph nodes. Total
lymph nodes: number of nodes tested. Positive nodes: number of
nodes showing cancer metastasis. (*) destroyed tissue.
Found at: doi:10.1371/journal.pone.0008929.s005 (0.12 MB
DOC)
Table S3 Individual patients’ immunohistochemical analysis for
KLF6, ERBB2 and Estrogen receptors. KLF6 (nuclear and
cytoplasmic) and ERBB2 (cytoplasmic membrane) stain intensity
are represented as score scale (0.0–4.0). (+)/(2): indicates if nuclear
KLF6 and ERBB2 wasconsidered positive or negative, respectively.
(22) not specified parameter. ND: None determined.
Found at: doi:10.1371/journal.pone.0008929.s006 (0.14 MB
DOC)
Table S4 Cell Cycle status of MCF-7 transfected with KLF6
specific siRNA. MCF-7 cells were transfected with scrambled
(SCR) or KLF6 specific siRNAs (A and B) as indicated (see also
[25]). For flow cytometric cell cycle analysis cells were harvested
after 72 h, fixed in 70% ethanol, treated with RNase A (125 mg/
ml) and propidium iodide (20 ug/ml), analyzed using a cytometer
apparatus and evaluated with Cylchred software. The experiment
was conducted in triplicates. Statistical analysis was performed
using a one-way ANOVA-Bonferroni analysis where p values,
0.05 were considered significant.
Found at: doi:10.1371/journal.pone.0008929.s007 (0.03 MB
DOC)
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